Original ContributionPARP-1 expression as a prognostic factor in Desmoid-type fibromatosis
Introduction
Desmoid-type fibromatoses, also known as desmoid tumors (DT), are non-metastasizing fibroblastic neoplasms with locally invasive growth. DT are rare with an incidence of 5 per million per year in the general population [1]. The exact pathogenesis of DT is unknown. There is, however, broad evidence of WNT signalling in DT [2]. DT are often associated with mutations in the CTNNB1-gene encoding for β-Catenin [3]. Treatment of DT can be challenging [4]. Pharmacologic strategies include non-steroidal anti-inflammatory drugs, tyrosine kinase inhibitors and cytostatic chemotherapy [5]. Tamoxifen, a selective estrogen receptor modulator, has demonstrated some efficacy in the treatment of DT which underlines the implication of steroid hormone receptors in the pathogenesis of DT [6].
In this study, we investigated the expression of hormone receptors, i.e. estrogen receptors (ER, in mRNA analyses: ESR) 1 (α) and 2 (β), androgen receptor (AR) and progesterone receptor (PR, in mRNA analyses: PgR), as well as the expression of the enzyme Poly Adenosine Diphosphate Ribose Polymerase-1 (PARP-1) and the protein Ki-67 in DT. To our knowledge, the expression of PARP-1 in DT has never been analyzed before. Immunohistochemical analyses of steroid hormone receptor expression vary [7,8]. ERβ seems to be more frequently expressed than ERα [[8], [9], [10]]. Nevertheless positive ER expression does not necessarily imply a therapeutic response to antiestrogens [11]. PARP-1 is part of a nuclear enzyme family which is involved in the repair of single-stranded DNA breaks [12]. PARP-1 expression in DT could be promising, as PARP-1 inhibition showed chemotherapy reinforcing effects in the treatment of Ewing-Sarcoma [13].
The purpose of this study was to investigate correlations between expression levels and established clinicopathological factors, i.e. tumor size, tumor localization, sex, age, resection margin and others in terms of a potential predictive or prognostic influence by means of immunohistochemistry (IHC) and quantitative Real-Time-PCR (qRT-PCR).
Section snippets
Study population and histopathological examination
Sixty-nine tissue samples of DT diagnosed at Charité – Universitätsmedizin Berlin, Germany, between 2005 and 2015 were included in this study. These included 50 (72.5%) primary and 19 (27.5%) relapse tumors. Institutional ethics approval for this retrospective analysis was obtained. General handling procedures and storage conditions of the formalin-fixed and parrafin-embedded (FFPE) tissue samples were constant during the study period. Table 1 gives a summarized overview of patient
Expression of hormone receptors, PARP-1 and Ki-67 in IHC
Hormone receptors showed almost no nuclear positivity in IHC. Only ERβ showed heterogeneous cytoplasmic expression (Table 2) with an IRS between 0 and 4. PARP-1 showed stronger nuclear positivity with a nuclear IRS >0 in 57 of 58 stained cases with an IRS of up to 6. Most of the samples showed an IRS of 2 or 3 (47 of 58; 81.0%). There was no cytoplasmic expression. The tumors exhibited a mean proliferation Ki-67 index of 3.2%. Most of the tumors showed a Ki-67 index between 1 and 5% (n = 25;
Discussion
Our study demonstrates the value of PARP-1 expression in DT as an independent prognostic factor. Moreover, relapse tumors recur faster compared to primary tumors. Hormone receptors did not show any prognostic value in this study. To our knowledge, this is the largest study evaluating the expression of various hormone receptor with different methods in DT so far.
Apart from cytoplasmic ERβ expression, which is presumably artifactual, the other hormone receptors, i.e. ERα, PR, and AR, did not
Acknowledgements
The authors thank Ines Koch and Barbara Meyer-Bartell for their excellent technical assistance. We thank Juliana Andrici, MD, for proofreading and language editing.
Patient consent for publication
Not required.
Declaration of competing interest
None declared.
References (25)
- et al.
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors
Am J Pathol
(2008) - et al.
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
Ann Oncol
(2017) - et al.
Desmoid tumours treated with triphenylethylenes
Eur J Cancer
(1992) - et al.
A comparison of methods for the analysis of low abundance proteins in desmoid tumor cells
Anal Biochem
(2006) - et al.
Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study
Ann Surg Oncol
(2015) - et al.
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis
Genes Chromosomes Cancer
(2015) - et al.
Advanced aggressive fibromatosis: effective palliation with chemotherapy
Acta Oncol
(2011) - et al.
Expression profiles of sex steroid receptors in desmoid tumors
Tohoku J Exp Med
(2006) - et al.
Immunohistochemical analysis of desmoid tumours
J Clin Pathol
(2005) - et al.
Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options
Biosci Trends
(2010)
Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-beta, COX2 and sex steroid receptors
Cancer Sci
Multifocal desmoids
Surgery
Cited by (5)
Management of Desmoid Tumors
2022, Surgical Oncology Clinics of North AmericaCitation Excerpt :Thus, the indication to active surveillance as a first-line treatment should be maintained in this subset of patients, whenever possible.8,26 Similarly, although DT can appear or progress during pregnancy,17 they usually tend to regress after delivery; thus, pregnancy per se does not constitute an indication for first-line aggressive treatment.5,26 In FAP-associated DT, resection of the primary tumor or early start of a pharmacologic treatment needs to be considered earlier, owing to a higher risk of complications, including intestinal obstruction, perforation, and mesenteric ischemia.
Novel insights into biomarkers of progression in Desmoid tumor
2023, Frontiers in OncologyMolecular-genetic landscape of abdominal and retroperitoneal desmoid fibromatosis: a retrospective study
2023, Journal of Modern Oncology